University Of Chicago

Selinexor maintenance after systemic therapy extended median PFS more than four times longer than placebo for women with advanced or recurrent TP53 wild-type endometrial cancer, according to phase 3 study results.

In statin-treated patients with dyslipidemia, the combination of obicetrapib and ezetimibe further lowered LDL, according to the results of the phase 2 ROSE2 trial.

CHICAGO — Survivors of high-risk neuroblastoma face a substantial burden of late toxicity, according to study results presented at ASCO Annual Meeting.

University of Chicago Medicine Comprehensive Cancer Center has joined the National Comprehensive Cancer Network as its 33rd member institution.

Racial and ethnic subtype-specific differences in pathologic complete response rates after neoadjuvant chemotherapy for breast cancer may partially account for worse survival rates for Black women, according to study data.

Black patients with pulmonary fibrosis are younger at diagnosis and death than Hispanic and white patients with pulmonary fibrosis, according to study results published in JAMA Network Open.

The ECHO-Chicago program — the first urban-centered ECHO program — improved self-efficacy across multiple clinical topics, ranging from behavioral health to hypertension, according to researchers.

Efficacy and safety of firibastat vs. placebo in adults with uncontrolled primary hypertension.

CHICAGO — In adults with difficult-to-treat and resistant hypertension, firibastat failed to demonstrate efficacy to lower unattended office systolic BP, according to findings from the FRESH trial.

The Kidney Cancer Association posthumously presented Nicholas J. Vogelzang, MD, FACP, FASCO, with a new award named in his honor.